Galavit, 25 mg 20 pcs.

Immunomodulatory and anti-inflammatory agent.

CodeATH: L03 Pharmacological properties:

Pharmacodynamics

The mechanism of action of the drug is associated with its ability to regulate the functional and metabolic activity of cells of innate and adaptive immunity (monocytes, macrophages, neutrophils, natural killers, etc.).

Galavit normalizes phagocytic activity of monocytes/macrophages, bactericidal activity of neutrophils and cytotoxic activity of NK-cells. At the same time by restoring the reduced activity of cells of innate and adaptive immunity the preparation increases resistance of the organism to infectious diseases of bacterial, viral and fungal etiology, promotes faster elimination of the pathogen from the organism, reduces the frequency, severity and duration of infections.

Galavit decreases production of reactive oxygen species by hyperactivated macrophages thus reducing oxidative stress and protecting tissues and organs from damaging effects of radicals. Normalization of excessively elevated functional activity of phagocytic cells leads to restoration of their antigen-presenting and regulatory functions and reduction of autoaggression level.

The drug is well tolerated and has no allergizing, mutagenic, embryotoxic, teratogenic and carcinogenic action.

Pharmacokinetics

Extracted from the body mainly through the kidneys. With sublingual administration the elimination half-life is 30 minutes. The main pharmacological effects are observed within 72 hours.

Indications

In adults and adolescents over 12 years of age (including those with secondary immune deficiency) as an immunomodulatory and anti-inflammatory agent in complex therapy:

acute respiratory infections, diseases of the respiratory tract and ENT organs (including often recurrent ones) of bacterial and viral etiology (ARVI, influenza, bronchitis, pneumonia, tonsillitis, otitis, adenoiditis) and their prevention;
inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases;
chronic recurrent diseases caused by the herpes virus;
decreased physical performance (including among athletes).

Pharmacological effect

Immunomodulatory and anti-inflammatory agent.

ATX code: L03
Pharmacological properties:

Pharmacodynamics

The mechanism of action of the drug is associated with its ability to regulate the functional and metabolic activity of innate and adaptive immune cells (monocytes, macrophages, neutrophils, natural killer cells, etc.).

Galavit normalizes the phagocytic activity of monocytes/macrophages, the bactericidal activity of neutrophils and the cytotoxic activity of NK cells. At the same time, by restoring the reduced activity of innate and adaptive immune cells, the drug increases the body’s resistance to infectious diseases of bacterial, viral and fungal etiology, promotes faster elimination of the pathogen from the body, and reduces the frequency, severity and duration of infections.

In addition, Galavit normalizes antibody formation, increases the functional activity (affinity) of antibodies, and indirectly regulates the production of endogenous interferons (IFN-a, IFN-γ) by producing cells. In inflammatory diseases, the drug reversibly inhibits for 6-8 hours the excessive synthesis of tumor necrosis factor-a, interleukin-1, interleukin-6 and other pro-inflammatory cytokines by hyperactivated macrophages, the level of which determines the degree of inflammatory reactions, their cyclicity, as well as the severity of intoxication of the body.

Galavit reduces the production of reactive oxygen species by hyperactivated macrophages, thereby reducing the level of oxidative stress and protecting tissues and organs from the destructive effects of radicals. Normalization of excessively increased functional activity of phagocytic cells leads to the restoration of their antigen-presenting and regulatory functions, and a decrease in the level of autoaggression.

The drug is well tolerated and has no allergenic, mutagenic, embryotoxic, teratogenic or carcinogenic effects.

Pharmacokinetics

It is excreted from the body mainly through the kidneys. When administered sublingually, the half-life is 30 minutes. The main pharmacological effects are observed within 72 hours.

Special instructions

The drug contains sorbitol; patients with rare hereditary pathologies associated with fructose and sorbitol intolerance should not take the drug.

Impact on the ability to drive vehicles and machinery:

The drug does not affect the ability to drive vehicles or operate machinery.

Active ingredient

Sodium aminodihydrophthalazindione

Composition

1 tab. contains:

Active substances:

sodium aminodihydrophthalazindione – 25 mg

Excipients:

sorbitol – 0.315 g,

starch – 0.14 g,

lactose – 0.1 g,

calcium stearate – 0.005 g,

talc – 0.015 g,

racementhol (menthol) – 0.0001 g.

Pregnancy

The drug is contraindicated in pregnant women and women during breastfeeding.

Contraindications

Individual intolerance, intolerance to galactose, fructose, lactase deficiency or glucose-galactose malabsorption, pregnancy and breastfeeding, children under 12 years of age.

Side Effects

In rare cases, allergic reactions are possible.

If you experience the side effects listed in the instructions or they get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

With simultaneous use, it is possible to reduce the course doses of antibiotics. Galavit allows you to increase the effectiveness of antibiotic therapy and reduce its side effects.

There are no cases of incompatibility with other drugs.

Overdose

No cases of overdose have been reported.

Storage conditions

Store at a temperature not exceeding 25°C, protected from light.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiration date indicated on the carton.

Manufacturer

Selvim, Russia